The global market for biopharmaceutical processing equipment and consumables is expected to hit $116.4 billion as demand for biologics and biosimilars rises. Manufacturers face pressure to meet stricter quality and regulatory standards, leading to increased investment in new technologies and infrastructure.
Single-use systems replace stainless steel
Disposable bioprocessing technologies are replacing traditional stainless-steel systems. These setups cut contamination risks, speed up production, and lower costs—advantages that matter most for companies scaling up biologics manufacturing. The change is most noticeable in facilities handling cell and gene therapies, where flexible, small-batch equipment is needed.
Contract development and manufacturing organizations are driving growth by purchasing bioreactors, chromatography systems, and automation tools. Their expansion has pushed equipment suppliers to develop new solutions faster.
Related: Ageing, chronic diseases push APAC medtech toward $132b
Automation and AI reshape production
New technologies are speeding up upgrades across the industry. Automated bioreactors, continuous bioprocessing, and AI-powered manufacturing are now common, helping companies improve yields and reduce errors. These improvements are changing biologics production from lab development to full-scale manufacturing.
Vaccine production and pandemic preparedness efforts have increased demand further. Governments and manufacturers are investing in processing equipment to prepare for future health crises. Strict good manufacturing practice rules also require reliable, high-performance systems.
Regional growth shifts east
North America leads the market, generating about 38% of global revenue in 2025. Its strong biopharmaceutical manufacturing base, steady R&D funding, and growing production of monoclonal antibodies, vaccines, and cell and gene therapies support this position.
Europe comes next, with growth fueled by an established manufacturing sector and wider use of continuous bioprocessing. The fastest growth, however, is in Asia-Pacific. China, India, South Korea, and Japan are expanding biologics production quickly, backed by government policies and a rise in CDMO capacity. Their efforts to reduce imports and build self-sufficiency are opening new opportunities for equipment suppliers.
Related: Brighton hospital gets new scanning equipment
If trends continue, the market may grow faster than expected. The push to develop advanced therapies, especially for cancer and rare diseases, could require even more specialized equipment. Companies offering scalable, modular solutions may have an advantage, particularly as smaller biotech firms enter the field with limited funds but ambitious plans.
The pace of adoption will depend on regulatory clarity and whether manufacturers can balance cost with innovation. While single-use systems lead today, hybrid approaches mixing disposable and stainless-steel components might become a compromise. These could attract manufacturers wanting flexibility without fully replacing older infrastructure.
AI’s role in predictive maintenance and process optimization is still new. Its potential to cut downtime and boost efficiency could make it standard within ten years.